<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Systemic therapeutic efficacy is central to determining the outcome of patients with <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>In these patients, there is a critical need for predictive biomarkers to optimize efficacy while minimizing toxicity </plain></SENT>
<SENT sid="2" pm="."><plain>The integration of a new generation of molecularly targeted drugs into the treatment of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e>, coupled with the development of sophisticated technologies for individual <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> as well as patient molecular profiling, underline the potential for personalized medicine </plain></SENT>
<SENT sid="3" pm="."><plain>In this review we focus on the latest progress made within the genomic and proteomic fields concerning predictive biomarkers for individualized therapy in <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e>. Â© 2013 The Association for the Publication of the Journal of Internal Medicine </plain></SENT>
</text></document>